Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC

CompletedOBSERVATIONAL
Enrollment

1,318

Participants

Timeline

Start Date

October 2, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

March 31, 2022

Conditions
Brain InjuriesConcussion, MildConcussion, BrainNear Point ConvergenceConcussion, Intermediate
Interventions
DEVICE

BrainScope Ahead 300iP-O

BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.

DIAGNOSTIC_TEST

SCAT5

Sports Concussion Assessment Tool 5

DIAGNOSTIC_TEST

Near Point Convergence

Manual ocular function measurement conducted only if electronic version on device fails

Trial Locations (6)

14642

University of Rochester Medical Center, Rochester

22042

INOVA Health System, Fairfax

33136

University of Miami, Miami

48824

Michigan State University, East Lansing

72701

University of Arkansas, Fayetteville

06269

University of Connecticut, Storrs

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

BrainScope Company, Inc.

INDUSTRY

NCT04074486 - Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC | Biotech Hunter | Biotech Hunter